OptiThyCARE™
Predicting and visualizing individual thyroid disease activity over months
Market launch 2026
OptiThyDOSE™
Calculating optimized individual thyroid disease dose in children and adults
Market launch 2028
Features
| Standard care | OptiThyCARE™ | OptiThyDOSE™ | |
|---|---|---|---|
| Predict and monitor with TSH and FT4 |  |
 |
|
| Predict and monitor with Heart Rate | |
|
N/a |
| Optimize individualized dosing | Assumed | Supported | Calculated |
| Risk of over- /underdosings | High | Low | Minimal |
| Regular blood tests and clinical visits | Requested | Optional | Minimal |
Benefits
Patients and their families
- Restores thyroid balance, reducing symptoms and improving well-being
- Lessens burden by reducing clinic visits and blood tests
- Promotes adherence and empowers patients
Clinicians and caregivers
- Enables optimized individual care
- Prevents over- and underdosing, improving clinical outcomes
- Detects non-adherence or early signs of disease reactivation
Public health
- Lowers costs by reducing need for clinical visits and blood tests
- Reduces disease- and treatment-related complications
- Improves long-term outcomes, particularly in children
Pharma & biotech companies
- Prevents underdosing and increases treatment effectiveness
- Strengthens clinician engagement and brand perception
- Reinforces the company’s innovative leadership image
- Supports protection and growth of market share
Portfolio and growth
-
2026
OptiThyCARE™
Thyroid diseases
-
2028
OptiThyDOSE™
Thyroid diseases
-
2030
OptiGrowthCARE
Growth hormone deficiency
-
2032
OptiGrowthDOSE
Growth hormone deficiency
Interested in our products?